Rehmann Capital Advisory Group’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $90.9K | Sell |
10,141
-1,375
| -12% | -$12.3K | 0.01% | 604 |
|
|
2025
Q1 | $86.4K | Hold |
11,516
| – | – | 0.01% | 598 |
|
|
2024
Q4 | $86.6K | Sell |
11,516
-450
| -4% | -$3.38K | 0.01% | 593 |
|
|
2024
Q3 | $90.9K | Sell |
11,966
-33
| -0.3% | -$251 | 0.01% | 589 |
|
|
2024
Q2 | $74.2K | Sell |
11,999
-75
| -0.6% | -$463 | 0.01% | 572 |
|
|
2024
Q1 | $61.3K | Hold |
12,074
| – | – | ﹤0.01% | 569 |
|
|
2023
Q4 | $72.3K | Sell |
12,074
-67
| -0.6% | -$401 | 0.01% | 548 |
|
|
2023
Q3 | $86K | Hold |
12,141
| – | – | 0.01% | 509 |
|
|
2023
Q2 | $85.5K | Hold |
12,141
| – | – | 0.01% | 530 |
|
|
2023
Q1 | $101K | Hold |
12,141
| – | – | 0.01% | 526 |
|
|
2022
Q4 | $139K | Hold |
12,141
| – | – | 0.01% | 528 |
|
|
2022
Q3 | $153K | Hold |
12,141
| – | – | 0.02% | 499 |
|
|
2022
Q2 | $128K | Hold |
12,141
| – | – | 0.01% | 481 |
|
|
2022
Q1 | $197K | Hold |
12,141
| – | – | 0.02% | 508 |
|
|
2021
Q4 | $168K | Buy |
+12,141
| New | +$168K | 0.02% | 532 |
|